Which has higher valuation & earnings, INDV or VTRS?

Indivior has higher earnings, but lower revenue than Viatris. Viatris is trading at a lower price-to-earnings ratio than Indivior, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Indivior $1.24B 3.95 $210M $1.95 20.57 Viatris $14.30B 1.40 -$3.51B -$0.26 N/A

Is INDV or VTRS more profitable?

Indivior has a net margin of 19.44% compared to Viatris' net margin of -2.04%. Viatris' return on equity of 19.04% beat Indivior's return on equity. Company Net Margins Return on Equity Return on Assets Indivior 19.44% -219.26% 29.40% Viatris -2.04% 19.04% 7.62%

Which has stronger earnings and valuation, INDV or GMAB?

Genmab A/S has higher revenue and earnings than Indivior. Indivior is trading at a lower price-to-earnings ratio than Genmab A/S, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Indivior $1.24B 3.95 $210M $1.95 20.57 Genmab A/S $3.72B 4.71 $963M $1.32 21.30

Is INDV or GMAB more profitable?

Genmab A/S has a net margin of 21.05% compared to Indivior's net margin of 19.44%. Genmab A/S's return on equity of 15.34% beat Indivior's return on equity. Company Net Margins Return on Equity Return on Assets Indivior 19.44% -219.26% 29.40% Genmab A/S 21.05% 15.34% 8.94%

Does the media prefer INDV or GMAB?

In the previous week, Genmab A/S had 6 more articles in the media than Indivior. MarketBeat recorded 10 mentions for Genmab A/S and 4 mentions for Indivior. Indivior's average media sentiment score of 0.42 beat Genmab A/S's score of 0.34 indicating that Indivior is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Indivior 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Genmab A/S 4 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has preferable valuation and earnings, ASND or INDV?

Indivior has higher revenue and earnings than Ascendis Pharma A/S. Indivior is trading at a lower price-to-earnings ratio than Ascendis Pharma A/S, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Ascendis Pharma A/S $814.57M 19.51 -$258M $8.67 29.38 Indivior $1.24B 3.95 $210M $1.95 20.57

Does the media prefer ASND or INDV?

In the previous week, Ascendis Pharma A/S had 2 more articles in the media than Indivior. MarketBeat recorded 6 mentions for Ascendis Pharma A/S and 4 mentions for Indivior. Ascendis Pharma A/S's average media sentiment score of 0.65 beat Indivior's score of 0.42 indicating that Ascendis Pharma A/S is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ascendis Pharma A/S 3 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 3 Negative mention(s) 0 Very Negative mention(s) Positive Indivior 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has stronger earnings and valuation, BBIO or INDV?

Indivior has higher revenue and earnings than BridgeBio Pharma. BridgeBio Pharma is trading at a lower price-to-earnings ratio than Indivior, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio BridgeBio Pharma $502.08M 31.85 -$724.93M -$3.74 N/A Indivior $1.24B 3.95 $210M $1.95 20.57

Does the media favor BBIO or INDV?

In the previous week, BridgeBio Pharma had 20 more articles in the media than Indivior. MarketBeat recorded 24 mentions for BridgeBio Pharma and 4 mentions for Indivior. BridgeBio Pharma's average media sentiment score of 0.72 beat Indivior's score of 0.42 indicating that BridgeBio Pharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BridgeBio Pharma 11 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Indivior 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer INDV or ELAN?

In the previous week, Elanco Animal Health had 5 more articles in the media than Indivior. MarketBeat recorded 9 mentions for Elanco Animal Health and 4 mentions for Indivior. Elanco Animal Health's average media sentiment score of 1.31 beat Indivior's score of 0.42 indicating that Elanco Animal Health is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Indivior 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Elanco Animal Health 8 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Indivior (INDV) Competitors

$40.11 -0.43 (-1.06%)

As of 01:52 PM Eastern

Compare

INDV vs. VTRS, GMAB, ASND, BBIO, and ELAN

Should you buy Indivior stock or one of its competitors? MarketBeat compares Indivior with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Indivior include Viatris (VTRS), Genmab A/S (GMAB), Ascendis Pharma A/S (ASND), BridgeBio Pharma (BBIO), and Elanco Animal Health (ELAN). These companies are all part of the "pharmaceutical products" industry.

How does Indivior compare to Viatris?

Indivior (NASDAQ:INDV) and Viatris (NASDAQ:VTRS) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their media sentiment, institutional ownership, analyst recommendations, dividends, profitability, valuation, risk and earnings.

Indivior has a net margin of 19.44% compared to Viatris' net margin of -2.04%. Viatris' return on equity of 19.04% beat Indivior's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Indivior	19.44%	-219.26%	29.40%
Viatris	-2.04%	19.04%	7.62%

Indivior has a beta of 0.86, suggesting that its share price is 14% less volatile than the broader market. Comparatively, Viatris has a beta of 0.91, suggesting that its share price is 9% less volatile than the broader market.

60.3% of Indivior shares are held by institutional investors. Comparatively, 79.9% of Viatris shares are held by institutional investors. 0.7% of Indivior shares are held by insiders. Comparatively, 0.3% of Viatris shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Indivior has higher earnings, but lower revenue than Viatris. Viatris is trading at a lower price-to-earnings ratio than Indivior, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Indivior	$1.24B	3.95	$210M	$1.95	20.57
Viatris	$14.30B	1.40	-$3.51B	-$0.26	N/A

In the previous week, Indivior had 4 more articles in the media than Viatris. MarketBeat recorded 4 mentions for Indivior and 0 mentions for Viatris. Indivior's average media sentiment score of 0.42 beat Viatris' score of 0.00 indicating that Indivior is being referred to more favorably in the media.

Company	Overall Sentiment
Indivior	Neutral
Viatris	Neutral

Indivior currently has a consensus price target of $40.29, indicating a potential upside of 0.44%. Viatris has a consensus price target of $17.50, indicating a potential upside of 2.13%. Given Viatris' higher possible upside, analysts plainly believe Viatris is more favorable than Indivior.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Indivior	0 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.75
Viatris	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43

Summary

Indivior beats Viatris on 11 of the 16 factors compared between the two stocks.

How does Indivior compare to Genmab A/S?

Indivior (NASDAQ:INDV) and Genmab A/S (NASDAQ:GMAB) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, risk, institutional ownership, valuation, media sentiment, earnings, analyst recommendations and dividends.

60.3% of Indivior shares are held by institutional investors. Comparatively, 7.1% of Genmab A/S shares are held by institutional investors. 0.7% of Indivior shares are held by company insiders. Comparatively, 1.5% of Genmab A/S shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Indivior currently has a consensus price target of $40.29, indicating a potential upside of 0.44%. Genmab A/S has a consensus price target of $38.21, indicating a potential upside of 35.92%. Given Genmab A/S's higher probable upside, analysts plainly believe Genmab A/S is more favorable than Indivior.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Indivior	0 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.75
Genmab A/S	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.75

Indivior has a beta of 0.86, meaning that its share price is 14% less volatile than the broader market. Comparatively, Genmab A/S has a beta of 0.84, meaning that its share price is 16% less volatile than the broader market.

In the previous week, Genmab A/S had 6 more articles in the media than Indivior. MarketBeat recorded 10 mentions for Genmab A/S and 4 mentions for Indivior. Indivior's average media sentiment score of 0.42 beat Genmab A/S's score of 0.34 indicating that Indivior is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Indivior	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Genmab A/S	4 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Genmab A/S has higher revenue and earnings than Indivior. Indivior is trading at a lower price-to-earnings ratio than Genmab A/S, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Indivior	$1.24B	3.95	$210M	$1.95	20.57
Genmab A/S	$3.72B	4.71	$963M	$1.32	21.30

Genmab A/S has a net margin of 21.05% compared to Indivior's net margin of 19.44%. Genmab A/S's return on equity of 15.34% beat Indivior's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Indivior	19.44%	-219.26%	29.40%
Genmab A/S	21.05%	15.34%	8.94%

Summary

Genmab A/S beats Indivior on 11 of the 16 factors compared between the two stocks.

How does Indivior compare to Ascendis Pharma A/S?

Ascendis Pharma A/S (NASDAQ:ASND) and Indivior (NASDAQ:INDV) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, dividends, profitability, analyst recommendations, institutional ownership, media sentiment, risk and valuation.

Ascendis Pharma A/S presently has a consensus target price of $295.67, indicating a potential upside of 16.06%. Indivior has a consensus target price of $40.29, indicating a potential upside of 0.44%. Given Ascendis Pharma A/S's stronger consensus rating and higher probable upside, research analysts plainly believe Ascendis Pharma A/S is more favorable than Indivior.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ascendis Pharma A/S	0 Sell rating(s)	1 Hold rating(s)	16 Buy rating(s)	2 Strong Buy rating(s)	3.05
Indivior	0 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.75

Ascendis Pharma A/S has a net margin of 57.87% compared to Indivior's net margin of 19.44%. Ascendis Pharma A/S's return on equity of 0.00% beat Indivior's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ascendis Pharma A/S	57.87%	N/A	-8.37%
Indivior	19.44%	-219.26%	29.40%

Ascendis Pharma A/S has a beta of 0.37, indicating that its stock price is 63% less volatile than the broader market. Comparatively, Indivior has a beta of 0.86, indicating that its stock price is 14% less volatile than the broader market.

In the previous week, Ascendis Pharma A/S had 2 more articles in the media than Indivior. MarketBeat recorded 6 mentions for Ascendis Pharma A/S and 4 mentions for Indivior. Ascendis Pharma A/S's average media sentiment score of 0.65 beat Indivior's score of 0.42 indicating that Ascendis Pharma A/S is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ascendis Pharma A/S	3 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	3 Negative mention(s)	0 Very Negative mention(s)	Positive
Indivior	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

60.3% of Indivior shares are held by institutional investors. 40.0% of Ascendis Pharma A/S shares are held by company insiders. Comparatively, 0.7% of Indivior shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Indivior has higher revenue and earnings than Ascendis Pharma A/S. Indivior is trading at a lower price-to-earnings ratio than Ascendis Pharma A/S, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ascendis Pharma A/S	$814.57M	19.51	-$258M	$8.67	29.38
Indivior	$1.24B	3.95	$210M	$1.95	20.57

Summary

Ascendis Pharma A/S beats Indivior on 12 of the 17 factors compared between the two stocks.

How does Indivior compare to BridgeBio Pharma?

BridgeBio Pharma (NASDAQ:BBIO) and Indivior (NASDAQ:INDV) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, analyst recommendations, profitability, dividends, institutional ownership, earnings, media sentiment and valuation.

Indivior has a net margin of 19.44% compared to BridgeBio Pharma's net margin of -124.42%. BridgeBio Pharma's return on equity of 0.00% beat Indivior's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BridgeBio Pharma	-124.42%	N/A	-65.81%
Indivior	19.44%	-219.26%	29.40%

Indivior has higher revenue and earnings than BridgeBio Pharma. BridgeBio Pharma is trading at a lower price-to-earnings ratio than Indivior, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BridgeBio Pharma	$502.08M	31.85	-$724.93M	-$3.74	N/A
Indivior	$1.24B	3.95	$210M	$1.95	20.57

BridgeBio Pharma currently has a consensus price target of $95.21, indicating a potential upside of 16.61%. Indivior has a consensus price target of $40.29, indicating a potential upside of 0.44%. Given BridgeBio Pharma's stronger consensus rating and higher possible upside, equities research analysts clearly believe BridgeBio Pharma is more favorable than Indivior.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BridgeBio Pharma	1 Sell rating(s)	2 Hold rating(s)	20 Buy rating(s)	0 Strong Buy rating(s)	2.83
Indivior	0 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.75

In the previous week, BridgeBio Pharma had 20 more articles in the media than Indivior. MarketBeat recorded 24 mentions for BridgeBio Pharma and 4 mentions for Indivior. BridgeBio Pharma's average media sentiment score of 0.72 beat Indivior's score of 0.42 indicating that BridgeBio Pharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BridgeBio Pharma	11 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Indivior	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

BridgeBio Pharma has a beta of 0.95, suggesting that its share price is 5% less volatile than the broader market. Comparatively, Indivior has a beta of 0.86, suggesting that its share price is 14% less volatile than the broader market.

99.9% of BridgeBio Pharma shares are owned by institutional investors. Comparatively, 60.3% of Indivior shares are owned by institutional investors. 14.2% of BridgeBio Pharma shares are owned by insiders. Comparatively, 0.7% of Indivior shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Summary

BridgeBio Pharma beats Indivior on 10 of the 16 factors compared between the two stocks.

How does Indivior compare to Elanco Animal Health?

Indivior (NASDAQ:INDV) and Elanco Animal Health (NYSE:ELAN) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, risk, institutional ownership, dividends, profitability, analyst recommendations, earnings and media sentiment.

Indivior currently has a consensus target price of $40.29, suggesting a potential upside of 0.44%. Elanco Animal Health has a consensus target price of $28.55, suggesting a potential upside of 11.76%. Given Elanco Animal Health's stronger consensus rating and higher possible upside, analysts clearly believe Elanco Animal Health is more favorable than Indivior.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Indivior	0 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.75
Elanco Animal Health	1 Sell rating(s)	2 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.77

Indivior has a beta of 0.86, indicating that its share price is 14% less volatile than the broader market. Comparatively, Elanco Animal Health has a beta of 1.68, indicating that its share price is 68% more volatile than the broader market.

In the previous week, Elanco Animal Health had 5 more articles in the media than Indivior. MarketBeat recorded 9 mentions for Elanco Animal Health and 4 mentions for Indivior. Elanco Animal Health's average media sentiment score of 1.31 beat Indivior's score of 0.42 indicating that Elanco Animal Health is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Indivior	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Elanco Animal Health	8 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Indivior has higher earnings, but lower revenue than Elanco Animal Health. Elanco Animal Health is trading at a lower price-to-earnings ratio than Indivior, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Indivior	$1.24B	3.95	$210M	$1.95	20.57
Elanco Animal Health	$4.72B	2.71	-$232M	-$0.50	N/A

60.3% of Indivior shares are owned by institutional investors. Comparatively, 97.5% of Elanco Animal Health shares are owned by institutional investors. 0.7% of Indivior shares are owned by company insiders. Comparatively, 1.1% of Elanco Animal Health shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Indivior has a net margin of 19.44% compared to Elanco Animal Health's net margin of -4.95%. Elanco Animal Health's return on equity of 7.42% beat Indivior's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Indivior	19.44%	-219.26%	29.40%
Elanco Animal Health	-4.95%	7.42%	3.66%

Summary

Elanco Animal Health beats Indivior on 11 of the 17 factors compared between the two stocks.

Get Indivior News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding INDV and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

INDV vs. The Competition

Export

Metric	Indivior	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$4.88B	$3.03B	$6.82B	$12.36B
Dividend Yield	N/A	2.05%	2.67%	9.36%
P/E Ratio	20.52	20.25	27.16	24.05
Price / Sales	3.95	778.53	573.09	112.68
Price / Cash	14.91	57.12	29.05	48.09
Price / Book	-51.42	4.21	10.68	6.18
Net Income	$210M	$65.46M	$3.59B	$331.63M
7 Day Performance	-0.25%	-2.56%	-1.56%	-1.49%
1 Month Performance	4.78%	-0.82%	1.10%	-1.21%
1 Year Performance	150.53%	17.30%	24.47%	17.67%

Indivior Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
INDV Indivior	2.2669 of 5 stars	$40.11 -1.1%	$40.29 +0.4%	+153.2%	$4.88B	$1.24B	20.52	1,051
VTRS Viatris	1.8066 of 5 stars	$16.28 -0.7%	$17.50 +7.5%	+94.7%	$18.95B	$14.30B	N/A	30,000
GMAB Genmab A/S	4.5645 of 5 stars	$28.48 -1.1%	$38.21 +34.2%	+31.3%	$17.74B	$3.72B	21.56	3,029
ASND Ascendis Pharma A/S	4.3997 of 5 stars	$264.37 -0.3%	$295.67 +11.8%	+53.6%	$16.49B	$814.57M	30.49	1,189	Analyst Downgrade
BBIO BridgeBio Pharma	3.4828 of 5 stars	$81.62 -1.8%	$94.63 +15.9%	+75.0%	$15.99B	$502.08M	N/A	400

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:INDV) was last updated on 7/20/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Indivior (INDV) Competitors

INDV vs. VTRS, GMAB, ASND, BBIO, and ELAN

How does Indivior compare to Viatris?

Summary

How does Indivior compare to Genmab A/S?

Summary

How does Indivior compare to Ascendis Pharma A/S?

Summary

How does Indivior compare to BridgeBio Pharma?

Summary

How does Indivior compare to Elanco Animal Health?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

INDV vs. The Competition

Indivior Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Indivior (INDV) Competitors

INDV vs. VTRS, GMAB, ASND, BBIO, and ELAN

How does Indivior compare to Viatris?

Is INDV or VTRS more profitable?

Which has more risk & volatility, INDV or VTRS?

Do insiders and institutionals believe in INDV or VTRS?

Which has higher valuation & earnings, INDV or VTRS?

Does the media prefer INDV or VTRS?

Do analysts prefer INDV or VTRS?

Summary

How does Indivior compare to Genmab A/S?

Do institutionals & insiders believe in INDV or GMAB?

Do analysts recommend INDV or GMAB?

Which has more risk and volatility, INDV or GMAB?

Does the media prefer INDV or GMAB?

Which has stronger earnings and valuation, INDV or GMAB?

Is INDV or GMAB more profitable?

Summary

How does Indivior compare to Ascendis Pharma A/S?

Do analysts rate ASND or INDV?

Is ASND or INDV more profitable?

Which has more volatility & risk, ASND or INDV?

Does the media prefer ASND or INDV?

Do insiders & institutionals believe in ASND or INDV?

Which has preferable valuation and earnings, ASND or INDV?

Summary

How does Indivior compare to BridgeBio Pharma?

Is BBIO or INDV more profitable?

Which has stronger earnings and valuation, BBIO or INDV?

Do analysts prefer BBIO or INDV?

Does the media favor BBIO or INDV?

Which has more risk and volatility, BBIO or INDV?

Do insiders & institutionals believe in BBIO or INDV?

Summary

How does Indivior compare to Elanco Animal Health?

Do analysts rate INDV or ELAN?

Which has more volatility & risk, INDV or ELAN?

Does the media prefer INDV or ELAN?

Which has better earnings and valuation, INDV or ELAN?

Do insiders & institutionals have more ownership in INDV or ELAN?

Is INDV or ELAN more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

INDV vs. The Competition

Indivior Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools